General Information of Drug Combination (ID: DCMMY8T)

Drug Combination Name
BRL-15572 Maprotiline
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs BRL-15572   DMM61Y2 Maprotiline   DMPWB7T
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 6.18
Bliss Independence Score: 6.18
Loewe Additivity Score: 15.76
LHighest Single Agent (HSA) Score: 15.77

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BRL-15572
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
BRL-15572 Interacts with 9 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [5]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [5]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [5]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [5]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [5]
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Agonist [5]
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [5]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [5]
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Agonist [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DTT(s)
Indication(s) of Maprotiline
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [3]
Major depressive disorder 6A70.3 Approved [4]
Mixed anxiety and depressive disorder N.A. Investigative [3]
Maprotiline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Maprotiline Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [7]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Maprotiline Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases ADR [8]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Increases Expression [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 10).
3 Maprotiline FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
6 Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
7 Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer. 2011 Apr 1;128(7):1712-23. doi: 10.1002/ijc.25477. Epub 2010 May 25.